Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
BBB-Therapeutics B.V.
ClinicalTrials.gov Identifier:
NCT01386580
First received: June 28, 2011
Last updated: September 30, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2014
  Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)